MedTrace Logo

Stage I/II NSCLC Perioperative Chemotherapy

NCT00198354 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2016-03-10

No results posted yet for this study

Summary

The addition of chemotherapy to lung cancer surgery is now considered as the standard of care. Solid data support postoperative chemotherapy but only few results are available in the preoperative setting. To define which timing of perioperative chemotherapy offers the best survival improvement, the IFCT 0002 study is conducted in France.

Conditions

  • Non-small Cell Lung Cancer Stage I and II
  • Peri-operative Chemotherapy

Interventions

DRUG

gemcitabine + cisplatine

gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)

DRUG

Paclitaxel + Carboplatine

paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Alain Depierre, Pr · Intergroupe Francophone de Cancerologie Thoracique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2009-12-31
Completion
2010-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198354 on ClinicalTrials.gov